Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Constrictive pericarditis caused by carbergoline].

Søren Pihlkjaer Hjortshøj1, Steen Hvitfeldt Poulsen, Jan Jesper Andreasen

  • 1Arhus Universitetshospital, Aalborg Sygehus, Kardiovaskulaert Forskningscenter, Kardiologisk Afdeling S, DK-9100 Aalborg. sph@dadlnet.dk

Ugeskrift for Laeger
|July 11, 2006
PubMed
Summary

Dopamine agonist cabergoline, used for Parkinson's disease, may cause constrictive pericarditis (CP). A patient treated with cabergoline developed CP, with thickened pericardium noted except in the myocardial infarction area, suggesting cabergoline as the likely cause.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter aortic valve implantation outcomes by patient age and sex in COMPARE-TAVI 1: a cohort study.

BMJ open·2026
Same author

Cardiac remodelling and functional status after cardiac resynchronization therapy: comparison between de-novo implantation and upgrade from right ventricular pacing.

ESC heart failure·2026
Same author

Contemporary Description of Clinical Characteristics and Outcomes in Patients with Hereditary ATTR Amyloidosis: Results from the Multicountry OverTTuRe Study.

Cardiology and therapy·2026
Same author

Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening.

JACC. Advances·2026
Same author

Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.

Journal of the American College of Cardiology·2026
Same author

Validity of Amyloidosis in the Danish National Patient Registry.

Clinical epidemiology·2026

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Dopamine agonists, such as pergolide and cabergoline, are utilized in Parkinson's disease treatment.
  • Constrictive pericarditis (CP) is a condition involving the thickening and stiffening of the pericardium.

Observation:

  • A 72-year-old male with Parkinson's disease (paralysis agitans) presented with clinical signs of constrictive pericarditis.
  • The patient had a history of myocardial infarction (MI) one year prior and had been on cabergoline therapy for four years.
  • Pericardiectomy revealed a significantly thickened pericardium (1-1.5 cm) encasing the right side of the heart, but the pericardium was normal in the area of the prior MI.

Findings:

  • The study suggests a potential association between cabergoline treatment and the development of constrictive pericarditis.

Related Experiment Videos

  • The localized absence of pericardial thickening over the myocardial infarction area points towards cabergoline as a probable etiological factor, differentiating it from ischemic causes.
  • This case highlights the potential for dopamine agonists to induce cardiac conditions beyond their intended therapeutic effects.

    • Implications:

    • Clinicians should consider the possibility of drug-induced constrictive pericarditis in patients treated with dopamine agonists like cabergoline.
    • Further research is warranted to elucidate the mechanisms by which cabergoline may contribute to pericardial disease.
    • This finding may influence treatment guidelines and patient monitoring for individuals on long-term dopamine agonist therapy for Parkinson's disease.